Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03299842 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome
A Phase 3 study, sponsored by Zogenix International Limited, Inc., a subsidiary of Zogenix.
- Terminated
- Registry status
- Phase 3
- Development phase
- 5
- Enrollment target
NCT03299842 is a Phase 3 study that was terminated before completion, run by Zogenix International Limited, Inc., a subsidiary of Zogenix. The registered enrollment target is 5 participants.
The verdict
NCT03299842, a Phase 3 study, was terminated before completion, sponsored by Zogenix International Limited, Inc., a subsidiary of Zogenix.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is an exploratory sub-study to ZX008-1503 \[NCT02823145\]. Subjects will be fitted with an Embrace seizure detection watch and seizures detected by the watch will be compared to those entered into an electronic seizure diary.
Interventions
- DRUG ZX008 (Fenfluramine Hydrochloride)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-07-12 |
| Est. Completion | 2018-07-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03299842
The ClinicalTrials.gov registry entry for NCT03299842 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zogenix International Limited, Inc., a subsidiary of Zogenix, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ZX008 (Fenfluramine Hydrochloride) is the first listed.
NCT03299842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03299842 about?
NCT03299842 is a clinical study titled "A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome". This is an exploratory sub-study to ZX008-1503 \[NCT02823145\]. Subjects will be fitted with an Embrace seizure detection watch and seizures detected by the watch will be compared to those entered into an electronic seizure diary.
What is the current status of trial NCT03299842?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 5 participants. The study started on 2017-07-12. Estimated completion is 2018-07-05.
What interventions are being tested in trial NCT03299842?
The interventions under investigation include: ZX008 (Fenfluramine Hydrochloride) (DRUG).
Who is sponsoring clinical trial NCT03299842?
This trial is sponsored by Zogenix International Limited, Inc., a subsidiary of Zogenix, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.